Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician's choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/KM10B). (October 2022)

• Record Type: Journal Article
• Authors: Sim, Sung Hoon; Kim, Jeong Eun; Kim, Min Hwan; Park, Yeon Hee; Kim, Jee Hyun; Suh, Koung Jin; Koh, Su-Jin; Park, Kyong Hwa; Kang, Myoung Joo; Ahn, Mi Sun; Lee, Kyoung Eun; Kim, Hee-Jun; Ahn, Hee Kyung; Kim, Han Jo; Park, Keon Uk; Byun, Jae Ho; Park, Jin Hyun; Lee, Gyeong-Won; Lee, Keun Seok; Sohn, Joohyuk; Jung, Kyung Hae; Park, In Hae
• Is Part Of: Breast. Volume 65(2022)
• Page Start: 172
• Page End: 178
• Publication Date: 2022-10
• Subjects: HER2 positive -- Metastatic breast cancer -- Trastuzumab biosimilar -- Clinical trial -- ctDNA; Breast -- Diseases -- Periodicals; Breast -- Tumors -- Periodicals; Breast -- Periodicals; Electronic journals; Periodicals; 616
• DOI: 10.1016/j.breast.2022.08.002
• Languages: English
• ISSNs: 0960-9776

Abstract

Abstract: We investigated the efficacy and safety of a trastuzumab biosimilar, Herzuma®, in combination with treatment of physician's choice (TPC) in patients with HER2+ metastatic breast cancer (MBC) who had failed at least two HER2 directed chemotherapies. Highlights: Treatment of HER2-positive breast cancer is rapidly evolving with the development of new agents. However, treatment options are still limited after progression with proven anti-HER2 therapies. The combination of chemotherapy with a trastuzumab biosimilar, Herzuma®, was effective and safe in patients with heavily pre-treated HER2+ MBC. Duration of response to previous anti-HER2 therapy, PIK3CA and ERBB2 mutations were associated with clinical efficacies of trastuzumab biosimilar plus chemotherapy.